HPV (human papilloma virus) predicts cervical radiotherapy efficacy:
This article was originally published in Clinica
Executive Summary
Testing for the human papilloma virus (HPV) in women with advanced cervical cancer could help predict how well the patients will respond to radiotherapy used to cure the disease, according to a Swiss study. Dr Katja Lindel and colleagues from the University Berne Hospital report that HPV is an independent prognostic parameter for clinical outcome and a predictive factor for radiation response. Results from their study of 40 patients treated with radiotherapy showed that HPV-positive women had slightly higher rates of overall survival and were significantly more likely to have their cancer go into remission than HPV-negative women, 67% versus 33%, respectively.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.